AIR Platform
Solid Tumors
PreclinicalActive
Key Facts
About VerImmune
VerImmune is pioneering a novel immunotherapy approach that leverages the body's existing immune memory against common pathogens to fight cancer. Its Anti-Tumor Immune Redirection (AIR) platform engineers bispecific molecules that bridge pathogen-specific T cells to tumor cells, aiming to activate a potent and targeted anti-cancer response. As a private, preclinical-stage biotech, the company's success hinges on validating its unique mechanism in the clinic and navigating the complex competitive landscape of immuno-oncology. If successful, AIR could offer a new therapeutic paradigm with the potential for strong efficacy and a favorable safety profile.
View full company profileTherapeutic Areas
Other Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| APVO603 | Aptevo Therapeutics | Preclinical |
| APVO711 | Aptevo Therapeutics | Preclinical |
| Platform-derived Immunotherapy | GenCirq | Pre-clinical |
| SP-2-225 | Shuttle Pharmaceuticals | Preclinical |
| SP-1-161 | Shuttle Pharmaceuticals | Preclinical |
| HBM1020 | Harbour BioMed | Phase 1 |
| HBM7022 | Harbour BioMed | Phase 1 |
| HBM9033 | Harbour BioMed | Discovery |
| Undisclosed Whole Cell Vaccine Program(s) | Neuvogen | Pre-clinical |
| SY-5609 | Syros Pharmaceuticals | Phase 1/2 |
| Not Specified (TCR Therapy) | T-Cure Bioscience | Phase 1 |
| B7-H3 Program | Ocean Biomedical | Discovery |